Price Crosses Moving Average
|Bid||5.90 x 1000|
|Ask||5.95 x 800|
|Day's Range||5.46 - 5.93|
|52 Week Range||2.71 - 6.50|
|Beta (5Y Monthly)||1.29|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 05, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||7.80|
It's been a mediocre week for Cerus Corporation (NASDAQ:CERS) shareholders, with the stock dropping 14% to US$5.31 in...
Ladies and gentlemen, thank you for standing by and welcome to the Cerus Corporation Q1 2020 Earnings Conference Call. It is now my pleasure to turn the call over to your host Mr. Tim Lee. With me on the call are Obi Greenman, Cerus' President and Chief Executive Officer; Kevin Green, Cerus' Chief Financial Officer; Vivek Jayaraman, our Chief Operating Officer; Dr. Laurence Corash, our Chief Scientific Officer; and Carol Moore, our Senior Vice President of Regulatory Affairs and Quality.
Cerus (CERS) delivered earnings and revenue surprises of 0.00% and 5.74%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Cerus Corporation (Nasdaq:CERS) announced today FDA regulatory approval for manufacture of INTERCEPT plasma with a new, alternative plastic disposable kit. The planned conversion to these new kits is part of the Company’s ongoing strategy to enhance its global supply chain integrity that was initiated several years ago.
Cerus Corporation (CERS) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.
Cerus (CERS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Cerus Corporation (Nasdaq:CERS) announced today that its first quarter 2020 financial results will be released on Tuesday, May 5, 2020, after the close of the stock market. The Company will host a conference call and webcast at 4:30 P.M. ET that afternoon, during which management will discuss the Company’s financial results and provide a general business overview and outlook.
Cerus Corporation (Nasdaq:CERS) today announced an amendment to the Company’s contract with the Biomedical Advanced Research and Development Authority (BARDA). The amendment provides an additional $14 million in available funding, increasing the total potential value of the contract to $214 million.
Passive investing in an index fund is a good way to ensure your own returns roughly match the overall market. Active...
Cerus Corporation (Nasdaq:CERS) today announced the Company’s recent activities related to COVID-19 and efforts to ensure that patients have readily available access to pathogen-reduced blood components, including convalescent plasma.
Cerus Corporation (Nasdaq: CERS) announced today that the University Hospital Basel transfused the first two COVID-19 patients with INTERCEPT treated coronavirus convalescent plasma (CCP). Cerus’ field team supported the INTERCEPT system implementation which was completed in one week.
Cerus Corporation (Nasdaq: CERS) announced today that the International Society of Blood Transfusion (ISBT) Working Party on Global Blood Safety issued a new document titled "Points to consider in the preparation and transfusion of COVID-19 convalescent plasma." The document was authored by Dr. Jay Epstein and Dr. Thierry Burnouf, two key opinion leaders in the field of transfusion medicine.
Cerus Corporation (Nasdaq: CERS) announced today that it has formed a collaborative research group with the aim of optimizing convalescent plasma therapy for COVID-19 patients. The research group seeks to define the key characteristics that influence the efficacy of convalescent plasma, including the level and nature of anti-COVID-19 antibodies, optimal collection timing, dosing and how these influence responses to the therapy regimen. Cerus’ research group collaborators include the California Department of Public Health, the University of California, Irvine’s Vaccine Development Research Laboratory, the Vitalant Research Institute, the California National Primate Research Center, and Enable Biosciences.
Cerus Corporation (Nasdaq:CERS) today announced the promotion of three key leaders within the Company in anticipation of the Company’s expected continued growth prospects, the anticipated approval and launch of multiple products over the next several years, as well as the need to realize greater operational effectiveness as the Company works to scale.
Airlines, hotels, casinos and other stocks continue to fall as fear of the coronavirus grows worldwide and all but halts activity in the virus epicenter of Wuhan, China. Alpha Pro Tech, Ltd. (NYSE: APT) manufactures masks and protective apparel — goods already in high demand in China. Lakeland Industries, Inc. (NASDAQ: LAKE) also produces protective clothes for high-risk workers, such as the medical professionals and public health officials exposing themselves to patients.
Investors in Cerus Corporation (NASDAQ:CERS) had a good week, as its shares rose 5.3% to close at US$5.16 following...
Whilst it may not be a huge deal, we thought it was good to see that the Cerus Corporation (NASDAQ:CERS) Independent...
Airlines, hotels, casinos and stocks linked to Wuhan, China, continue to fall as fear of the coronavirus deters international travel and all but halts activity in the virus epicenter. Alpha Pro Tech, Ltd. (NYSE: APT) manufactures masks and protective apparel — goods already in high demand in China. Lakeland Industries, Inc. (NASDAQ: LAKE) also produces protective clothes for high-risk workers, such as the medical professionals and public health officials exposing themselves to patients.